HDAC6-IN-29
HDAC6-IN-29 (compound 11g), hydroxamic analogue, is a HDAC6 inhibitor. HDAC6-IN-29 has potent antiproliferative activity against CAL-51 cells (IC50 = 1.17 μM) and is able to induce apoptosis and cause accumulation of cells in the S phase of the cell cycle. HDAC6-IN-29 can be used for the research of cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hdac6-in-29.html
Solubility
10 mM in DMSO
Smiles
O=C(NCCCCCCC(NO)=O)CCC[C@]1([H])[C@]2([H])[C@]3([H])[C@@](CCCN3CCC2)([H])CN1CC4=CC=CC5=C4C=CN5CC6=CC=C(F)C(Cl)=C6
Molecular Formula
C38H51ClFN5O3
Molecular Weight
680.29
References & Citations
[1]Dai L, et al. Exploring Derivatives of Quinolizidine Alkaloid Sophoridine in the Design and Biological Mechanistic Evaluation of Histone Deacetylase Inhibitors for Triple‐Negative Breast Cancer [J]. ChemMedChem, 2023: e202300467.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
